Brain Ischemia - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Ischemia - Pipeline Review, H2 2016, provides an overview of the Brain Ischemia (Central Nervous System) pipeline landscape.

Brain ischemia is a stroke is when the blood supply to any part of the brain is interrupted, resulting in tissue death and loss of brain function. The most common cause of stroke is atherosclerosis. Symptoms include loss of movement of body area, weakness, numbness, decreased vision, loss of memory, vertigo, loss of coordination and urinary incontinence. Treatment includes analgesics to control severe headache, anti-hypertensive medication to control high blood pressure and anti-platelet agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Ischemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Ischemia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 9 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Brain Ischemia.

Brain Ischemia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Ischemia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Ischemia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Ischemia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Ischemia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Ischemia (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Ischemia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Ischemia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Brain Ischemia Overview 7
Therapeutics Development 8
Pipeline Products for Brain Ischemia - Overview 8
Pipeline Products for Brain Ischemia - Comparative Analysis 9
Brain Ischemia - Therapeutics under Development by Companies 10
Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 11
Brain Ischemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Brain Ischemia - Products under Development by Companies 14
Brain Ischemia - Products under Investigation by Universities/Institutes 15
Brain Ischemia - Companies Involved in Therapeutics Development 16
CohBar, Inc. 16
Lixte Biotechnology Holdings, Inc. 17
NeuroNascent, Inc. 18
NeurOp, Inc 19
Prolong Pharmaceuticals, LLC 20
Spectrum Pharmaceuticals, Inc. 21
Sylentis S.A.U. 22
Vect-Horus S.A.S. 23
Brain Ischemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
2-CCPA - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AB-002 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ADA-409 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Humanin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
LAU-0901 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
LB-100 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
NP-10679 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
phycocyanobilin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Sanguinate - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules for Brain Ischemia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SPI-1620 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Stem Cell Therapy for Ischemia - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Synthetic Peptide for Central Nervous System Disorders - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
VHN-439 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Brain Ischemia - Dormant Projects 54
Brain Ischemia - Discontinued Products 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for Brain Ischemia, H2 2016 8
Number of Products under Development for Brain Ischemia - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Brain Ischemia - Pipeline by CohBar, Inc., H2 2016 16
Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 17
Brain Ischemia - Pipeline by NeuroNascent, Inc., H2 2016 18
Brain Ischemia - Pipeline by NeurOp, Inc, H2 2016 19
Brain Ischemia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 20
Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 21
Brain Ischemia - Pipeline by Sylentis S.A.U., H2 2016 22
Brain Ischemia - Pipeline by Vect-Horus S.A.S., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Brain Ischemia - Dormant Projects, H2 2016 54
Brain Ischemia - Dormant Projects (Contd..1), H2 2016 55
Brain Ischemia - Discontinued Products, H2 2016 56